DexCom (DXCM) is up 7.2% today. Here is some analysis on what might have caused this price movement. ([ca.investing.com](https://ca.investing.com/news/stock-market-news/truist-raises-dexcom-stock-price-target-to-87-on-growth-outlook-93CH-4738035))
Analysis: The most likely driver is a favorable analyst move, with Truist lifting its price target and pointing to improving growth visibility, possible coverage expansion catalysts, and room for margin upside. Recent product momentum, including a new Health Canada authorization for the G7 15 Day system, and a broader bid for medical device stocks may have added support. ([ca.investing.com](https://ca.investing.com/news/stock-market-news/truist-raises-dexcom-stock-price-target-to-87-on-growth-outlook-93CH-4738035))
Details:
Sources:
Dexcom Investor Relations, Health Canada, Investing.com
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$DXCM Insider Trading Activity
$DXCM insiders have traded $DXCM stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:
- KEVIN R SAYER (Executive Chair) has made 0 purchases and 2 sales selling 53,515 shares for an estimated $3,853,080.
- JON COLEMAN (EVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 9,823 shares for an estimated $722,628.
- MICHAEL JON BROWN (EVP Chief Legal Compliance Off) has made 0 purchases and 4 sales selling 6,800 shares for an estimated $447,695.
- MARK G FOLETTA has made 0 purchases and 2 sales selling 4,000 shares for an estimated $296,539.
- BRIDGETTE P HELLER has made 0 purchases and 2 sales selling 2,024 shares for an estimated $129,556.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$DXCM Hedge Fund Activity
We have seen 457 institutional investors add shares of $DXCM stock to their portfolio, and 386 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 6,252,665 shares (+203.4%) to their portfolio in Q1 2026, for an estimated $392,667,362
- JENNISON ASSOCIATES LLC removed 4,741,847 shares (-81.9%) from their portfolio in Q1 2026, for an estimated $297,787,991
- ALLIANCEBERNSTEIN L.P. added 4,299,512 shares (+49.9%) to their portfolio in Q1 2026, for an estimated $270,009,353
- NUVEEN, LLC removed 2,907,804 shares (-62.8%) from their portfolio in Q1 2026, for an estimated $182,610,091
- UBS GROUP AG added 2,426,179 shares (+126.1%) to their portfolio in Q1 2026, for an estimated $152,364,041
- TORONTO DOMINION BANK added 2,237,087 shares (+980.0%) to their portfolio in Q1 2026, for an estimated $140,489,063
- AMERIPRISE FINANCIAL INC added 2,112,533 shares (+99.3%) to their portfolio in Q1 2026, for an estimated $132,667,072
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$DXCM Congressional Stock Trading
Members of Congress have traded $DXCM stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:
- SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.
- SENATOR JOHN BOOZMAN purchased up to $15,000 on 01/26.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$DXCM Analyst Ratings
Wall Street analysts have issued reports on $DXCM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/13/2026
To track analyst ratings and price targets for $DXCM, check out Quiver Quantitative's $DXCM forecast page.
$DXCM Price Targets
Multiple analysts have issued price targets for $DXCM recently. We have seen 12 analysts offer price targets for $DXCM in the last 6 months, with a median target of $85.0.
Here are some recent targets:
- Kieran Ryan from Deutsche Bank set a target price of $86.0 on 06/23/2026
- Matt O'Brien from Piper Sandler set a target price of $88.0 on 06/15/2026
- Joshua Jennings from TD Cowen set a target price of $95.0 on 06/10/2026
- Anthony Petrone from Mizuho set a target price of $85.0 on 06/09/2026
- Jonathan Block from Stifel set a target price of $90.0 on 06/05/2026
- Joanne Wuensch from Citigroup set a target price of $84.0 on 05/28/2026
- Matt Miksic from Barclays set a target price of $64.0 on 05/18/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
